Colgate-Palmolive (CL)
Consumo básico / Cuidado del hogar y personal
The global oral care leader (~41% share of toothpaste) plus Hill's Pet Nutrition, a very high-quality business (~60% gross margin, century-old brands) but low growth (organic +1.4%, volume −0.4%). At $92 — near its 52-week low — the P/E on normalized earnings is ~25×, above the staples band; valuing at 20× normalized earnings (GAAP is depressed by a $794M impairment charge in the skin care business), 5-year base $96 (+4% with dividend): Preserves value.
- Price
- $91.64
- Intrinsic value (5y, base)
- $96
- Total annual return (5y)
- 3.5%
- Status (nominal)
- Preserves value
- Margin of safety
- No margin
The essentials
- Global oral care leader: ~41.3% global toothpaste share and ~32.4% manual toothbrush share, with the Colgate brand described in the filing itself as the one with the highest household penetration in the world; present in more than 200 countries, two-thirds of sales outside the United States, and ~45% in emerging markets.
- Very high-quality but low-growth business: ~60% gross margin and elevated return on invested capital, but in 2025 organic sales grew just +1.4% with volume declining (−0.4%) and toothpaste share giving up 0.4 points — price (+2.1%) is carrying growth while volume retreats.
- At $92 — near its 52-week low — it looks beaten down, but on normalized earnings it trades at ~25×, above the staples band and above Procter & Gamble / Kimberly-Clark (~22×). FY2025 GAAP is depressed by a $794M impairment charge (skin care/Filorga business); valuing at 20× normalized earnings, 5-year base $96: Preserves value.
Intrinsic value — two valuation methods
Total return at 5 years: 3.5%/year = 1.0% appreciation + 2.6% dividend. The target price ($96) is ex-dividend; the $12 in dividends collected over 5 years are added separately.
The methods disagree: one places the value today above the price ($92) and the other below.
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $92 trades ~4.7% above its value discounted to today (~$88); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Preserva valor: the target price ($96) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$56.
Thesis
The business
Colgate-Palmolive is one of the highest-quality consumer staples businesses in the world: global oral care leader (~41% toothpaste share), ~60% gross margin, century-old brands, and a growth franchise in Hill's. But it is a low-growth business: in 2025 organic sales grew +1.4% with consolidated volume declining, propped up by price, and toothpaste share lost ground. The $919M impairment in the skin care business also exposed a capital allocation misstep.
The valuation
A staple consumer good is valued on P/E on normalized net income. The FY2025 GAAP is depressed by the non-cash impairment charge of $794M after-tax (skin care business), so the relevant profit is what the company reports on a non-GAAP basis: $2,996M / $3.69 per diluted share. The base case projects that income growing modestly—price, gradual margin recovery as input costs normalize, and buyback reducing shares ~1.2% per year—at an exit multiple of 20× (mid-range of the 16-22× band for a staple consumer good, below Procter & Gamble / Kimberly-Clark due to weaker growth). That yields $96/share at five years.
The margin of safety
No margin of safety: at this price capital is preserved, but it is not bought below its value. The point is that, even near its 52-week low, Colgate trades on normalized earnings at ~25× — above the staples band and above its direct peers. The quality is beyond question, but the price already reflects it: the verdict is Preserves value, with the dividend (a Dividend King, 2.3%) contributing most of a modest total return. It is a great company at a full price, not a bargain.
What to watch
First, volume: growth rests on price while volume falls and toothpaste share declines—if elasticity sharpens or private label gains ground, the organic engine stalls. Second, gross margin: input costs subtracted 420 bps in 2025, and while productivity initiatives and pricing already offset 88% of that hit (net decline of just 40 bps), the thesis assumes the remainder normalizes. Third, capital allocation after the Filorga stumble: buyback has already been cut ~30% in dollars to protect the dividend, and book equity is anemic after decades of buybacks—watch that capital return remains sustainable on cash flow. The 2026 guidance (8-K of May 1st, maintained on sales and EPS, only revised down on gross margin for announced tariffs) falls within the projected path, so this reading does not change.
Educational / informational. Does not constitute investment advice.